Thyroid peroxidase Modulators
1 drugsAbout Thyroid peroxidase
Thyroid peroxidase (TPO) catalyzes iodination and coupling of tyrosine residues on thyroglobulin, essential for synthesizing thyroxine (T4) and triiodothyronine (T3). It plays a crucial role in thyroid hormone production.
TPO has emerged as a drug target, particularly in oncology, but there is currently no genetic evidence available to support its role in disease.
TPO is targeted by one FDA-approved drug, HICON, a small molecule used in oncology. JUBILANT is the sole company with an approved TPO-targeting drug.
Top Thyroid peroxidase Drugs
JUBILANT is the only company with an approved drug targeting TPO.
Low competition suggests a potential market opportunity, but also a high barrier to entry.
Thyroid peroxidase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Thyroid peroxidase, using small molecule modality.
The exclusive use of small molecules indicates a whitespace opportunity for other modalities like antibodies.
Thyroid peroxidase Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Thyroid peroxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 4 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Thyroid peroxidase Drug Approval Timeline (2003 - 2003)
The first and only drug, HICON, was approved in 2003.
The lack of recent approvals suggests market saturation or challenges in developing new TPO-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Thyroid peroxidase. A trial counts if an approved drug acting on Thyroid peroxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.